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In The Sum of Us: What Racism Costs Everyone, Heather McGhee argues,
persuasively, that the white desire to maintain position atop a racial hierarchy impedes
us from adopting or changing policies that would benefit everyone; even when white
citizens lose out on access to social benefits and economic opportunity, the fear of
Black citizens accessing those opportunities and benefits erodes support for universal
improvement. The author’s analysis, unfortunately, is applicable to my area of study –
U.S. drug policy. As Ms. McGhee briefly notes, the failure of American politics to
appropriately address the harms of substance use and substance use disorders reflects
“a bitter cost of the white majority’s willingness to accept the suffering of
others”(McGhee p. 47) and the ways in which that willingness also harms white people
is an additional cost we bear.
American drug policy, as I have noted elsewhere, and as others have documented, is
not incidentally racist – racial animus is at its core. The adoption of laws criminalizing
the kinds of substances we now consider to be illicit drugs was a twentieth-century
phenomenon, and each wave of criminalization reflected white anxiety about non-white
immigrant groups (opium, Chinese immigrants in the beginning of the 20th century;
marijuana, Mexican immigrants in the 1930s) or Black Americans (cocaine, particularly
crack cocaine). The historical association of substance use as intrinsically connected to
race never was rooted in reality; even as new laws in the 1980s assumed crack cocaine
was associated with Black Americans, the majority of crack cocaine users were white.
As with the other areas of policy McGhee identifies, the decision to treat substance use
and attendant issues as a problem for criminal law – the decision to remove people
from communities and to identify them as persons in need of punishment – is one that
disproportionately affects Black Americans, but one where white Americans also
experience harm.
When drug pandemics are conceptualized as white, the rhetoric and responsive policy
may be less punitive. I have written about the mid-2000s public concern around
methamphetamine use and its portrayal as an epidemic plaguing rural white
communities, and the extent to which we did not create new criminal laws and increase
available punishments at the pace we saw for the crack cocaine pandemic that was
conceptualized as Black. White politicians would describe how methamphetamine use
affected their families; a summit of governors generated a list of proposed tools to
curtail methamphetamine harms, and mentioned the word “incarceration” only in the
context of a proposal to consider “alternatives to incarceration.” Still, while white

empathy was on display, methamphetamine remained an illicit drug punished by arrest
and prosecution; when Montana created a special methamphetamine prison with
directed services for persons with substance use disorders, those services still were
being provided in an incarcerative facility to people convicted of crimes.
We are now witnessing a new drug pandemic associated with white Americans. The
harms of opioid misuse have been widely publicized, often sympathetically; portraits of
persons harmed by substance use often depict either (white) people who start using
opioid medication for prescribed pain management and develop a dependence that
exceeds the duration of the prescription, or (white) people who live in depressed
communities who turn to opioid use to medicate despair. McGhee briefly notes this
development in her book (McGhee p. 47), and, as someone who has been studying the
opioid epidemic in the context of our fifty-year War on Drugs, I think she is right to
think that how our response to the opioid pandemic is playing out unfortunately
supports the thesis for her book.
Even in a drug epidemic that is harming more white people than Black, states and the
federal government have largely adhered to a prosecution-and-punishment based
approach to the harms of substance use, damaging people and communities who are
already vulnerable. Efforts to treat the opioid epidemic as a public health crisis have
largely been stymied – when several U.S. cities expressed a willingness to partner with
providers to establish supervised consumption sites, as I have documented elsewhere,
they faced state and federal opposition, and threats of withdrawn funding and
prosecution. When rhetoric is empathetic to people with substance use disorders, it
often takes the form of “this person is sick, not a criminal” – the status of being a
criminal is what is at stake, as we now commonly understand the lifetime repercussions
of criminal convictions for people who want to be employed, housed, and accepted
into communities. White voters may be concerned that, without the ability to mark
people as criminal, it is more difficult for them to remain atop the racial hierarchy – and
since, even if substance use is consistent across races, the majority of people serving
time for drug offenses are nonwhite, equality threatens the ability of white voters to
maintain status.
I try to share McGhee’s optimism that we can work together across racial lines to
change the drug policy that harms all of our communities. Oregon has recently
decriminalized drug possession, and, after years of stalled plans, New York City
recently opened supervised consumption sites. Hopefully a recognition of the harms
of our failed criminal justice approach to substance use, and a shared desire to help
people in need, will change our course for the future.
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